KHB(SZ:002022)2023-05-12 07:18Company Overview - Shanghai Kehua Bio-engineering Co., Ltd. was established in 1981 and is the first company listed on the Shenzhen Stock Exchange's SME board in the IVD sector [2] - The company specializes in the R&D, production, and sales of in vitro diagnostic reagents and medical testing instruments, covering molecular diagnostics, biochemical diagnostics, immunodiagnostics, and rapid diagnostics [2] - Kehua's products are distributed across over 30 provinces and municipalities in China, serving more than 12,000 hospitals and over 500 disease control centers, blood centers, blood stations, biopharmaceutical companies, and research institutes, with exports to over 100 countries and regions [2] Business Strategy - The company aims to achieve full industry chain coverage by enhancing R&D investment, strengthening business integration, and optimizing its supply chain [3] - Future development plans include focusing on internal capabilities, collaborating with international giants, and expanding overseas business [3] Financial and Operational Insights - The company manages customer credit through tiered management, offering 3-6 month payment terms to strong partners while using upfront payment models for new clients [3] - The board decided not to adjust the conversion price of the company's convertible bonds, maintaining confidence in long-term development [4] Market Trends and Challenges - The company embraces centralized procurement and domestic substitution trends, aiming to enhance market influence and optimize costs [4] - In 2023, Kehua plans to focus on core products and leverage opportunities from centralized procurement and domestic substitution [4] Shareholder Matters - A significant arbitration case with minority shareholders of Tianlong Company has been resolved amicably, with both parties committed to the company's high-quality development [4] - In May 2020, Zhuhai Baolian acquired shares of Kehua Bio for 1,725,534,684 yuan, purchasing 95,863,038 ordinary shares [4]